The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants

Patients with chronic myeloid leukemia (CML) show resistance to tyrosine kinase inhibitors (TKIs) targeting ABL1 due to the emergence of BCR::ABL1 mutants, especially compound mutants during the treatment, which brings great challenges to clinical practice. Combination therapy is an effective strate...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Wu, Wu, Xia, Wang, Xiaojia, Wei, Xiaoyu, Tang, Yuqian, Ouyang, Xianfeng, Gong, Yuping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574342/
https://www.ncbi.nlm.nih.gov/pubmed/36263131
http://dx.doi.org/10.3389/fphar.2022.931772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574342/
https://www.ncbi.nlm.nih.gov/pubmed/36263131
http://dx.doi.org/10.3389/fphar.2022.931772

Ejemplares similares